Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): Data from the French Multicentre Retrospective FORSYA Study
RMD Open. 2024; 10(1):e003942 DOI 10.1136/rmdopen-2023-003942
Patients in France who started secukinumab therapy further from the launch of secukinumab were more likely to receive it as a first- or second-line therapy than patients who started treatment shortly after its launch, and had a higher retention rate when used as a first line treatment.
Dougados, et al. stratified patients into two groups: the first cohort received secukinumab during 16 August 2016–31 August 2018, while the second cohort started treatment from 1 September 2018–13 November 2020. Secukinumab was launched in France in August 2016. This retrospective multicentre French study compared retention rates of secukinumab in patients with axSpA by time of treatment initiation.
Keywords:
